Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 15/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544421 | 0.87 | ACKR3 (0.72) | ACKR3MC4RMC5RMC3R | |
| SCHEMBL3539270 | 0.85 | ACKR3 (1.00) | ACKR3MC4RMC5RMC3RLPAR1 | |
| SCHEMBL3539267 | 0.85 | ACKR3 (1.00) | ACKR3MC4RMC5RMC3RLPAR1 | |
| SCHEMBL3614587 | 0.82 | ACKR3 (0.83) | ACKR3MC4RMC5RMC3RLPAR1 | |
| SCHEMBL3614590 | 0.82 | ACKR3 (0.83) | ACKR3MC4RMC5RMC3RLPAR1 | |
| SCHEMBL13890982 | 0.81 | ACKR3 (0.77) | ACKR3 | |
| SCHEMBL12410221 | 0.78 | ACKR3 (0.85) | ACKR3 | |
| SCHEMBL3536235 | 0.78 | ACKR3 (0.85) | ACKR3 | |
| SCHEMBL3541045 | 0.77 | ACKR3 (0.84) | ACKR3 | |
| SCHEMBL12410212 | 0.77 | ACKR3 (0.84) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | CHEMOCENTRYX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | CHEMOCENTRYX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | VEGFA, FLT4, PGF | ACKR3 336/4885MC4R 1298/4885MC5R 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.